Bimatoprost

Class: Prostaglandin Analogs
VA Class: OP109
Chemical Name: (Z)-7-[(1R,2R,3R,5S)-3,5,Dihydroxy-2-[1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-5-N-ethylheptenamide
Molecular Formula: C₂₅H₃₇NO₄
Brands: Latisse, Lumigan

Medically reviewed by Drugs.com on Jun 21, 2021. Written by ASHP.

Introduction

Ocular hypotensive agent; a synthetic prostaglandin analog.

Uses for Bimatoprost

Ocular Hypertension and Glaucoma

Bimatoprost 0.01 or 0.03% ophthalmic solution (Lumigan or generic formulations, respectively): Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

Bimatoprost 0.03% at least as effective as latanoprost 0.005% in controlling diurnal IOP; may be more effective than timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension.

When selecting an initial ocular hypotensive agent, consider extent of the required IOP reduction, coexisting medical conditions, and drug characteristics (e.g., dosing frequency, adverse effects, cost). With single-agent regimens, the reduction in IOP is approximately 25–33% with topical prostaglandin analogs; 20–25% with topical β-adrenergic blocking agents, α-adrenergic agonists, or miotic (parasympathomimetic) agents; 20–30% with oral carbonic anhydrase inhibitors; 18% with topical rho kinase inhibitors; and 15–20% with topical carbonic anhydrase inhibitors.

A prostaglandin analog frequently is considered for initial therapy in the absence of other considerations (e.g., contraindications, cost considerations, intolerance, adverse effects, patient refusal) because of relatively greater activity, once-daily administration, and low frequency of systemic adverse effects; however, ocular adverse effects can occur.

Goal is to maintain an IOP at which visual field loss is unlikely to substantially reduce quality of life during the patient's lifetime.

Reduction of pretreatment IOP by ≥25% shown to slow progression of primary open-angle glaucoma. Set an initial target IOP...